

Fiscal 2010 Financial Results

May 10, 2011

Isao Teshirogi, Ph. D. President and Chief Executive Officer





Forward-Looking Statements

- This presentation contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements.
- Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products.
- The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
- This material contains information on pharmaceuticals (including compounds under development), but this information is not intended to make any representations or advertisements regarding the efficacy or effectiveness of these preparations nor provide medical advice of any kinds.





Overview of FY2010 Results





Financial Results (Consolidated)

(Units: billion yen)

<consolidated></consolidated>	FY2010 Forecasts	FY2010 Results	Achievement (%)	Forecasting Variance	FY2009 Results	Y on Y Change (%)	Y on Y Change
Sales	283.0	282.3	99.8	(0.7)	278.5	1.4	3.8
Operating income	54.0	46.8	86.8	(7.2)	52.4	(10.6)	(5.6)
Ordinary income	51.5	45.1	87.7	(6.4)	50.5	(10.6)	(5.4)
Net income	30.0	20.0	66.8	(10.0)	38.6	(48.2)	(18.6)

Due to change in the accounting periods, results in FY2010 include 15 months from Jan. 2010 to Mar. 2011 for the U.S. subsidiaries.



Financial Position and Cash Flows (Consolidated)

(* Units: billion yen)

<financial position=""></financial>	3/31/2011	3/31/2010	Y on Y Change
Total assets*	523.2	540.7	(17.5)
Net assets*	328.0	341.9	(13.9)
Equity ratio (%)	62.7	63.2	(0.5)
Net assets per share (yen)	979	1,019	(40)

(Units: billion yen)

<cash flows=""></cash>	FY2010 Results	FY2009 Results	Y on Y Change
Net cash provided by operating activities	56.5	52.9	3.6
Net cash provided by investing activities	(13.9)	(0.8)	(13.1)
Net cash provided by financing activities	(27.0)	(4.9)	(22.1)
Net increase (decrease)	13.0	46.1	(33.1)
Cash and cash equivalents at end of period	110.6	97.6	13.0





Sales by Segments (Consolidated)

(Units: billion yen)

	FY2010 Forecasts	FY2010 Results	Achievement (%)	Forecasting Variance	FY2009 Results	Y on Y Change (%)	Y on Y Change
Prescription drugs	155.4	158.9	102.3	3.5	152.5	4.2	6.4
Crestor	29.2	29.0	99.2	(0.2)	24.2	19.8	4.8
Irbetan	7.8	7.3	93.1	(0.5)	3.8	93.2	3.5
Cymbalta	2.6	2.7	102.3	0.1	Ι	_	2.7
Total of 3 key products	39.6	38.9	98.2	(0.7)	27.9	39.2	11.0
OxyContin	9.8	9.6	98.3	(0.2)	8.5	13.2	1.1
Finibax	4.0	3.6	89.1	(0.4)	3.4	6.0	0.2
Differin	3.0	3.2	106.3	0.2	2.2	46.4	1.0
Pirespa	3.0	2.8	91.8	(0.2)	1.5	80.9	1.3
Rapiacta	1.8	0.3	15.6	(1.5)	0.6	(49.1)	(0.3)
Total of 8 strategic products	61.2	58.3	95.3	(2.9)	44.1	32.3	14.2
Flomox	20.1	21.9	108.9	1.8	24.0	(8.8)	(2.1)
Claritin	8.2	10.0	121.7	1.8	9.0	10.5	1.0
Rinderon	9.1	9.5	104.6	0.4	9.5	0.5	0
Flumarin	6.9	7.5	109.0	0.6	8.7	(13.6)	(1.2)
Export/Overseas subsidiaries	43.2	37.4	86.6	(5.8)	49.1	(23.7)	(11.7)
Shionogi Inc.	32.9	27.0	82.2	(5.9)	38.6	(30.0)	(11.6)
Doripenem	5.4	4.7	86.6	(0.7)	5.2	(10.7)	(0.5)
Contract manufacturing	4.4	5.4	123.0	1.0	7.4	(27.1)	(2.0)
OTC and quasi-drugs	5.5	5.2	94.1	(0.3)	5.4	(4.9)	(0.2)
Diagnostics	2.8	2.9	102.1	0.1	2.9	(2.9)	(0)
Royalty income	68.3	68.9	100.9	0.6	57.0	20.9	11.9
Crestor	63.5	64.2	101.2	0.7	50.0	28.5	14.2
Others	3.4	3.6	107.0	0.2	4.1	(10.5)	(0.5)
Total	283.0	282.3	99.8	(0.7)	278.5	1.4	3.8

Statements of Income (Consolidated)



Statements a	(Units: bi	llion yen)					
	FY2010 Forecasts	FY2010 Results	Achievement (%)	Forecasting Variance	FY2009 Results	Y on Y Change (%)	Y on Y Change
Sales	283.0	282.3	99.8	(0.7)	278.5	1.4	3.8
[Royalty income]	[68.3]	[68.9]	[100.9]	[0.6]	[57.0]	[20.9]	[11.9]
Cost of sales	27.0 [35.5] 76.3	28.9 [38.3] 81.7	107.1	5.4	27.4 [34.4] 76.2	7.2	5.5
Gross profit	206.7	200.6	97.1	(6.1)	202.2	(0.8)	(1.6)
SG&A expenses	54.0 152.7	54.4 153.7	100.7	1.0	53.8 149.8	2.6	3.9
Selling & general expenses	99.2	102.8	103.6	3.6	97.9	4.9	4.9
R&D expenses	53.5	50.9	95.2	(2.6)	51.8	(1.7)	(0.9)
Operating income	19.1 54.0	16.6 46.8	86.8	(7.2)	18.8 52.4	(10.6)	(5.6)
Non-operating income and expenses	L2.5	L1.7		0.8	L1.9		
Ordinary income	18.2 51.5	16.0 45.1	87.7	(6.4)	18.1 50.5	(10.6)	(5.4)
Extraordinary income and loss	L4.2	L12.0		(7.8)	P8.0		
Income before income taxes	47.3	33.1		(14.2)	58.5		
Total income taxes	17.3	13.1	75.8	(4.2)	19.9	(34.2)	(6.8)
Net income	30.0	20.0	66.8	(10.0)	38.6	(48.2)	(18.6)

Small numbers in red are percentages of sales, and numbers in red provided in parentheses are percentages of royalty excluded sales. 6



(Units: upper/million dollar, lower/billion yen)

	FY2010	FY2010	Achievement	Forecasting		FY2	2010 Resu	lts *	
	Forecasts	Results	(%)	Variance	Jan-Mar 2010	Apr-Jun	Jul-Sep	Oct-Dec	Jan-Mar 2011
Sales	382 32.9	312 27.0	81.7	(70) (5.9)	110 10.1	56 5.1	69 5.8	68 5.6	9 0.4
Cost of sales	82 7.1	79 6.8	96.3	(3) (0.3)	18 1.6	23 2.1	15 1.3	12 1.0	10 0.8
SG&A expenses	324 27.9	312 27.0	96.2	(12) (0.8)	76 7.0	83 7.6	54 4.6	55 4.5	44 3.5
Operating income	(24) (2.1)	(80) (6.9)	-	(56) (4.8)	16 1.5	(51) (4.6)	(1) (0)	1 0.1	(46) (3.9)
Extraordinary loss	L144 L12.4	L173 L15.0	—	(29) (2.6)	_	L25 L2.3	L47 L4.2	L62 L5.4	L38 L3.2

*: Due to change in the accounting periods, results in FY2010 include 15 months for the U.S. subsidiaries.

<Reasons for business under performance from Jan. to Mar. 2011>

- Decrease of sales due to termination of marketing agreement of some primary care products
- Increase of allowance for the revenue deductions
- Additional extraordinary loss of about 1.8 billion yen relating to collection uncertainties in addition to anticipated business restructuring costs and impairment loss

Difference between Forecasts and Results



(Units: billion yen)

Sales: (0.7) Forecast 283.0 / Result 282.3

Prescription drugs (Japan):	+ 3.5
Shionogi Inc.:	(5.9)
Contract manufacturing:	+ 1.0 - Increased costs for Cymbalta etc.
Royalty income:	+ 0.6
• Other departments:	+ 0.1

Operating income: (7.2) Forecast 54.0 / Result 46.8

Decrease in gross profit:	(6.1)	 Increased cost to sales ratio Decreased sales in Shionogi Inc. Delays in reducing cost of sales
Increase in SG&A expenses:	+ 1.0	 Impact of the earthquake
Selling & general expenses:	+ 3.6	- Increased selling cost and delays in cost reductions
R&D expenses:	(2.6)	- Reduced development costs in Shionogi Inc.

Difference between Forecasts and Results



(Units: billion yen)

Net income: (10.0) Forecast 30.0 / Result 20.0

Extraordinary income:	+ 6.2	
Sales of idle real estate and investment securities:	+ 5.7	
> Others:	+ 0.5	
Extraordinary loss:	(18.3)	
Impact of the Great Eastern Japan Earthquake:	(3.0)	
Impairment loss:	(7.3)	 Intangible assets related to discontinued products in Shionogi Inc.
Business structure improvement expense	es: (4.8)	 Consolidation of U.S. operations in New Jersey
Collection uncertainties:	(1.8)	- Shionogi Inc.
Cost for recall:	(0.5)	- Shionogi Inc.
> Others:	(0.8)	

Note: As the described numerical value is rounded, the total value might not agree with the sum of individual numerical values.





Review of FY2010 Results

Japanese domestic sales (prescription drugs)

- Robust sales increase of 4.2% compared with FY2009 results despite the reduction in NHI drug prices
- Increase of 32.3% year on year in the sales of 8 strategic products as a result of increased focus

Crestor royalty

• Vigorous growth of 28.5% year on year as a result of global sales expansion

Shionogi Inc.

- Decreased sales due to increased generic competition and deductions for non-promoted primary care products
- Stabilize financial results of U.S. operations in FY2011 and beyond aided by the adoption of more conservative accounting procedures
- U.S. operations are now managed by tightly integrated and highly committed Japanese and U.S. management teams, after difficulties in the integration process from Atlanta into New Jersey





FY2011 Financial Forecasts





Financial Forecasts (Consolidated)

(Units: billion yen)

<consolidated></consolidated>	FY2011 Forecasts	1 st Half FY2011 Forecasts	FY2010 Results	Y on Y Change (%)	Y on Y Change
Sales	286.0	137.5	282.3	1.3	3.7
Operating income	58.0	24.5	46.8	23.7	11.2
Ordinary income	56.0	23.5	45.1	24.0	10.9
Net income	37.0	15.5	20.0	84.8	17.0





Sales by Segments (Consolidated)

(Units: billion yen)

	FY2011	1 st Half FY2011	FY2010	Y on Y	Y on Y
	Forecasts	Forecasts	Results	Change (%)	Change
Prescription drugs	166.8	80.4	158.9	5.0	7.9
Crestor	37.0	17.6	29.0	27.8	8.0
Irbetan	10.5	4.8	7.3	44.5	3.2
Cymbalta	5.5	2.5	2.7	106.8	2.8
Total of 3 key products	53.0	24.9	38.9	36.3	14.1
OxyContin	10.5	5.1	9.6	9.0	0.9
Finibax	4.2	2.0	3.6	17.9	0.6
Differin	4.1	1.9	3.2	28.6	0.9
Pirespa	3.4	1.6	2.8	23.4	0.6
Rapiacta	1.5	0.1	0.3	435.5	1.2
Total of 8 strategic products	76.7	35.6	58.3	31.6	18.4
Flomox	19.0	9.0	21.9	(13.2)	(2.9)
Claritin	7.5	3.5	10.0	(24.9)	(2.5)
Rinderon	9.2	4.5	9.5	(3.4)	(0.3)
Flumarin	6.2	3.3	7.5	(17.5)	(1.3)
Export/Overseas subsidiaries	33.5	15.8	37.4	(10.5)	(3.9)
Shionogi Inc.	22.4	10.2	27.0	(17.2)	(4.6)
Doripenem	5.0	2.4	4.7	6.9	0.3
Contract manufacturing	5.9	2.6	5.4	9.1	0.5
OTC and quasi-drugs	5.1	2.5	5.2	(1.5)	(0.1)
Diagnostics	2.7	1.2	2.9	(5.6)	(0.2)
Royalty income	70.0	34.0	68.9	1.6	1.1
Crestor	67.0	32.0	64.2	4.3	2.8
Others	2.0	1.0	3.6	(45.0)	(1.6)
Total	286.0	137.5	282.3	1.3	3.7



Statements of Operating Income (Consolidated)

(Units: billion yen)

	FY2011 Forecasts	1 st Half FY2011 Forecasts	FY2010 Results	Y on Y Change (%)	Y on Y Change
Sales	286.0	137.5	282.3	1.3	3.7
[Royalty income]	[70.0]	[34.0]	[68.9]	[1.6]	1.1
	26.9 [35.6]	27.3 [36.2]	28.9 [38.3]		
Cost of sales	77.0	37.5	81.7	(5.8)	(4.7)
Gross profit	209.0	100.0	200.6	4.2	8.4
	52.8	54.9	54.4		
SG&A expenses	151.0	75.5	153.7	(1.8)	(2.7)
Selling & general expenses	94.0	47.0	102.8	(8.6)	(8.8)
R&D expenses	57.0	28.5	50.9	11.9	6.1
Operating income	20.3 58.0	17.8 24.5	16.6 46.8	23.7	11.2

Small numbers in red are percentages of sales, and numbers in red provided in parentheses are percentages of royalty excluded sales.





Forecasts of Shionogi Inc.

	FY2011 Forecasts	1 st Half FY2011 Forecasts	FY2010 Results	Y on Y Change (%)	Y on Y Change
Sales	280 22.4	128 10.2	312 27.0	(10.3)	(32) (4.6)
Cost of sales	34 2.7	16 1.2	79 6.8	(57.0)	(45) (4.1)
SG&A expenses	244 19.5	122 9.7	312 27.0	(21.8)	(68) (7.5)
Operating income	1 0.1	(10) (0.8)	(80) (6.9)	-	81 7.0

(Units: upper/million dollar, lower/billion yen)

Assumed exchange rates: 87 yen (FY2010) and 80 yen (FY2011) to the dollar





Key Issue to Achieve the FY2011 Forecasts

Japanese domestic sales (Prescription drugs)

- Further focus on newly launched products (8 strategic products)
- Increase of hospital market share with stronger presence
- Enhancing the productivity per sales representative with better cost control

Expense control

- Cost of sales
 - Review of suppliers of raw materials and manufacturing processes including internally manufactured products

SG&A expenses

Increased budget control and improved response to changes in the business environment by careful prioritization of all expenses during FY2011 budget planning process





Key Issue to Achieve the FY2011 Forecasts

Pipeline

- Continuing to enrich the development pipeline with appropriate prioritization
- Target milestones of the key pipeline products in FY2011
 - **S-349572;** Global : Phase III enrollment completed
 - > Ospemifene; U.S. : BE study completion, NDA filing
 - S-297995; U.S. : Phase IIa completion, Phase IIb initiation, Japan : Phase IIb initiation
 - S-707106; U.S. : Phase IIa completion, Go/No-Go decision

Crestor royalty

- Sustainable growth in the global market
- Enhancement of collaboration with AstraZeneca, proactively addressing changes in the global market trend of Crestor[®] after the launch of Lipitor[®] generics



BE: Bioequivalence 1




Action against Key Issue Shionogi Inc.

- Expand sales by strengthening the product portfolio
 - ➢ Enhance presence in the pediatrics market with the launches of KAPVAY[™] and CUVPOSA[™]
 - Augment product lineup through in-licensing activities
 - Contribute to the mid to long term sales of Shionogi Group by the development and launch of new global products including Ospemifene, PSD502 and S-297995
- Stabilize product supply by rapidly addressing quality issues
 - Experts from Shionogi Japan supervising contract manufacturers to improve product quality
- Stabilize business performance
 - More stable results achieved through tight focus on product sales and reducing variability in deductions
- Smooth and effective integration and operation of U.S. business
 - Unifying the direction of all employees, including management, toward the same goal

Shareholder Return

Dividend Policy

- FY2010 forecast: 40 yen as planned
- FY2011 forecast: 40 yen
- Sustain the consolidated payout ratio of 35% based on the 3rd Medium-Term Business Plan and return the profit to shareholders in case the financial result exceeds FY2011 forecast











Change of Phases (since January 2011)

Newly launched

 CUVPOSATM (Glycopyrrolate, Anticholinergic, Oral): Chronic moderate-to-severe drooling in pediatric patients
 USA: Launched April 2011

Approved

• Finibax[®] (Carbapenem antibiotic, Injection):

Serious infection,

Additional new dosage regimen

Japan: Approved April 2011





Change of Phases (since January 2011)

Change of Phases

• S-297995 (Peripheral opioid receptor antagonist, Oral):

Alleviation of opioid-induced adverse effects

Started Phase IIb in Japan (Anti-constipation)

• S-524101 (Sublingual tablet of house-dust mite allergen extracts for immunotherapy):

Allergic rhinitis caused by house-dust mite allergen

Started Phase I in Japan

Discontinued development

SHIONOGI & CO., LTD.

• S-2367 (NPY Y5 receptor antagonist, Oral): Obesity

> Development in USA and expansion into EU

• S-888711 (Small molecule TPO mimetic, Oral): Thrombocytopenia

Development for ITP in EU and USA

NPY: Neuropeptide Y, TPO: Thrombopoietin, ITP: Immune Thrombocytopenia 22




International Industry-Academic Collaboration Initiatives

Industrial-academic collaboration initiative in Denmark

Main elements


- Matching innovations in research institutions in Denmark with the drugdiscovery technology and needs of Shionogi
- Establishing cooperative research relationships with those institutions by embarking on joint research for new drug 'seeds'
- Personnel exchanges to facilitate international human resources development
- Further accelerate the globalization of Shionogi's activities





SHIONOGI & CO., LTD.

LAP: Long acting parenteral formulation, DNP: Diabetic neuropathic pain







Target Milestones for FY2011

Progress in global development products			
S-349572 (Dolutegravir)*	Global: Phase III enrollment completed		
S-2367 (Japan) S-234462	Go/No-Go decision		
Ospemifene	US: BE study completion, NDA filing		
S-555739	Japan: Phase IIa completion, Go/No-Go decision		
S-297995	US: Phase IIa completion, Phase IIb initiation Japan: Phase IIb initiation		
S-707106	US: Phase IIa completion, Go/No-Go decision		
S-888711 (chronic liver disease)	Japan: Phase IIa completion, Go/No-Go decision		
S-288310	Japan: Phase I/II in progress (enrollment completed)		
S-488410	Japan: Phase I/II in progress (enrollment completed)		
S-222611	US/EU: Phase Ib in progress (enrollment completed)		
S-265744 LAP*	US: Phase I completion		
FTIH: more than 3 compounds			

*: Developed by Shionogi-ViiV Healthcare LLC, LAP: Long-acting parenteral formulation